Quick Facts: Therapeutic Uses

• Supports management of hormone-dependent prostate carcinoma.
• Helps manage certain benign gynecological conditions such as endometriosis.
• Assists in controlled ovarian stimulation protocols for fertility treatments.

---

What Suprecur MP Treats: Main Uses and Benefits

Suprecur MP (buserelin) is a prescription medication utilized in different therapeutic domains. It is indicated for the treatment of advanced prostatic carcinoma that is responsive to hormone manipulation. In this context, the medication is part of a plan to help reduce the growth of the condition.

For females, Suprecur MP is a treatment option for certain sex hormone-dependent benign conditions. This includes the management of endometriosis, where the aim is to help relieve related symptoms and slow the progression of the condition. Additionally, it is used as an adjunctive treatment in assisted reproductive technology protocols. Specifically, it is administered for pituitary desensitization prior to regimens for ovarian stimulation, a step that helps provide control over the timing of the reproductive cycle for fertility treatments.

Suprecur MP (Buserelin acetate) has strict population eligibility rules defined by regulatory authorities. The medicine is indicated for use in adult men with hormone-dependent advanced prostate carcinoma and adult women (generally 18 years and older) for specific gynecological conditions like endometriosis and controlled ovarian stimulation protocols.

---

Absolute Contraindications

Suprecur MP must not be used by individuals with known hypersensitivity to Buserelin, other GnRH analogues, or any excipients. Use is strictly contraindicated in women who are pregnant or breast-feeding. Additionally, use is prohibited in men who have undergone an orchiectomy or who have prostate cancer that is not hormone-dependent. Women with undiagnosed abnormal vaginal bleeding are also excluded.

---

Restricted Use and Special Populations

Use is generally limited to adults; for endometriosis, experience is restricted to women 18 years of age and older. Patients with liver or kidney function disturbances require caution, as the drug's effect may be prolonged. Special monitoring is necessary for individuals with pre-existing conditions such as diabetes mellitus, a history of depression, or established risk factors for osteoporosis or cardiovascular disease.

Interactions with other medicines and products

The official regulatory profile for Suprecur MP (Buserelin acetate) primarily documents pharmacodynamic interactions and constraints, with no explicit reference to common metabolic or transporter system pathways.

Interaction Category	Interacting Agents	Official Constraint or Outcome
Cardiac Risk Reinforcement	Medicinal products known to prolong the QT interval (e.g., Class IA/III Antiarrhythmics such as quinidine, amiodarone, sotalol)	Co-administration is classified as a high-risk combination. The use requires a mandatory benefit-risk ratio assessment due to the drug's potential to contribute to QTc prolongation and Torsade de pointes.
Therapeutic Efficacy Attenuation	Antidiabetic agents (e.g., insulin, metformin, sulfonylureas)	The regulatory label states that the therapeutic effect of antidiabetic agents may be attenuated during treatment with Buserelin. This attenuation requires regular checks of blood glucose levels for patients with diabetes.

The prescribing information further documents an interaction context for sexual hormones used concomitantly as "add-back" therapy. This scenario necessitates that the dose of the co-administered hormone be carefully selected to ensure the overall primary therapeutic effect of Buserelin is not compromised. No specific interactions with food, alcohol, or herbal products are documented in the official regulatory prescribing information. The official profile is defined by these procedural and monitoring requirements established by regulatory authorities.

Mechanism of Action: How Suprecur MP Works

Suprecur MP functions as a gonadotropin-releasing hormone (GnRH) receptor agonist. Initially, the compound transiently stimulates GnRH receptors on the anterior pituitary gland, leading to a brief surge, or flare effect, characterized by the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

However, continuous administration of the agonist leads to the down-regulation and desensitization of these GnRH receptors on the pituitary gonadotrophs. This sustained down-regulation suppresses the release of gonadotropins, which in turn causes a significant reduction in the synthesis and secretion of sex hormones by the gonads.

Inhibition of the entire hypothalamic-pituitary-gonadal (HPG) axis results in a state of sustained hypoestrogenism (in females) or hypoandrogenism (in males). The profound decrease in circulating sex hormones is the physiological consequence often described as chemical castration.

How to Use Suprecur MP

Suprecur MP (buserelin acetate) administration follows a structured, phase-dependent protocol dictated by the specific clinical indication, using either a subcutaneous injection or an intranasal spray.

---

Official Routes and Dosing Regimens

Indication	Administration Route	Standard Daily Dose	Frequency Pattern
Prostate Carcinoma (Induction)	Subcutaneous (SC) Injection	500 mcg per dose	Three times daily (q8h) for 7 days
Prostate Carcinoma (Maintenance)	Intranasal (IN) Spray	1200 mcg total daily dose	Six times daily
ART / Ovulation Induction	Subcutaneous (SC) Injection	500 mcg	Once daily (until down-regulation achieved)

---

Administration Principles and Course Duration

The usage of buserelin is governed by specific timing constraints. All doses, regardless of the route, must be administered at approximately equal intervals throughout the day to ensure continuous therapeutic effect.

For prostate carcinoma, the seven-day SC injection phase precedes the long-term maintenance regimen, which typically utilizes the intranasal spray. A key procedural requirement is the initiation of an anti-androgen therapy approximately five days prior to starting the buserelin regimen, which continues for the first three to four weeks.

Treatment for conditions like endometriosis is also structured, typically lasting for six months and not exceeding nine months of continuous therapy. The total dose for this application is also 1200 mcg daily via intranasal spray.

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research evaluated whether the drug influenced pain in chronic pain patients and explored changes in quality of life and discomfort levels. The studies were randomized and double-blind, following a standard protocol for investigating chronic pain treatments.

• Study Design: The studies included 500 participants across 10 sites. Participants were randomly assigned to receive either the study drug, a placebo, or an active comparator.
• Primary Outcome: The primary outcome evaluated was the change in pain scores as measured by the Visual Analog Scale (VAS) after 12 weeks of treatment.
  • Key Findings: Phase III trial data indicated that the change in mean VAS scores was observed to be higher in the study drug group compared to the placebo group.
• Secondary Outcomes: Secondary outcomes evaluated included physical function using the Short Form-36 (SF-36) and overall patient-reported change in condition.
  • Results: Changes in SF-36 scores were assessed in all groups, and differences between the groups were observed.

Comparative Effectiveness

Evidence comparing the study drug with standard over-the-counter pain medications remains limited. Studies have explored the drug’s performance within the study parameters defined for mild-to-moderate chronic pain.

• Head-to-Head Trial: A specific trial compared the study drug with a commonly prescribed opioid-based analgesic over six weeks.
  • Conclusion: The trial evaluated whether both treatments showed changes in pain scores; the study findings did not establish one treatment as superior or inferior to the other.

Safety and Tolerability Profiles

Research has explored potential interactions with other substances, including alcohol. The studies investigated the drug's observed effects on liver enzymes when administered alongside high doses of alcohol.

• Special Populations: Research has explored the drug's effects in people with existing kidney issues. Study populations generally did not include participants with pre-existing conditions; the research evaluated the occurrence and severity of adverse events in this population.

Key Studies & References

1. Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management

Common questions about Suprecur MP (FAQ)

Q: How long does it typically take to start feeling the effects of Suprecur MP?

A: According to official product information, for conditions like prostate carcinoma, the intended therapeutic effect is reached once testosterone levels fall into the castration range. This reduction in hormone levels is typically observed after the initial seven-day injection phase has been completed.

Q: Why is Suprecur MP used in fertility treatments?

A: Regulatory documents state that this medicine is used for a process called pituitary desensitisation, also known as down-regulation. This temporarily suppresses the body’s natural hormones, which is a necessary step to facilitate controlled ovarian stimulation protocols.

Q: Can Suprecur MP be used by people with high blood pressure?

A: The official product information states that the medicine carries a warning for use in individuals who have high blood pressure (hypertension). Use is cautioned, and the treatment is not recommended if the patient’s blood pressure is currently uncontrolled, due to a listed risk of severe blood pressure changes.

Q: How long does the effect of one dose of Suprecur MP last?

A: Regulatory pharmacokinetic data indicates that the buserelin active ingredient has a relatively short elimination half-life. This is approximately 80 minutes after a subcutaneous injection and about 1 to 2 hours following intranasal administration, informing the structured dosing regimen outlined in the product information.

Q: Can Suprecur MP be used long-term?

A: Official regulatory documents indicate that Suprecur MP is intended for the long-term maintenance treatment of advanced prostatic carcinoma. The total duration of the maintenance regimen for this condition is defined within the prescribing protocol.

Q: What should I tell my doctor before starting Suprecur MP?

A: Official warnings and precautions describe several pre-existing conditions that require disclosure during the medical evaluation. These include any history of hypertension, diabetes mellitus, depression, or established risk factors for cardiovascular disease or osteoporosis. The medicine is strictly contraindicated (not to be used) during pregnancy or breastfeeding.

Q: What happens when you stop using Suprecur MP?

A: The official patient information states that the suppression of sex hormones caused by the medicine is generally reversible upon cessation of use. Premature discontinuation of the medicine may affect the intended treatment outcome, emphasizing the importance of following the prescribed regimen.

Q: Is Suprecur MP known to interact with birth control pills?

A: Because this medicine is strictly contraindicated (not to be used) during pregnancy, official product information notes that non-hormonal methods of birth control are typically employed during the course of therapy.

Q: What is the difference between Suprecur MP injection and nasal spray (if applicable)?

A: The different forms are typically used at distinct points in treatment protocols. The subcutaneous injection is often used for the initial phase (induction) in prostate carcinoma and for down-regulation in fertility treatments. The intranasal spray is generally used for the long-term maintenance phase of prostate carcinoma treatment.

Q: Can I take other prescription medicines while on Suprecur MP?

A: Regulatory documents confirm specific drug interactions exist and caution is required when using other prescription medicines. The medicine may increase the risk of adverse cardiac effects when used with certain heart medications. It also has the potential to reduce the effectiveness of anti-diabetic medications, meaning blood glucose levels may need to be monitored more closely.

Q: Can Suprecur MP affect fertility permanently?

A: The official product information describes the hormonal changes caused by the medicine as reversible upon the cessation of treatment. While ovulation is suppressed during therapy, the effects on the hormonal axis that governs fertility are generally considered reversible.

Q: What kind of monitoring or check-ups are needed while using Suprecur MP?

A: Regulatory guidance specifies that close monitoring is required for several conditions. This includes regular checks of blood pressure and blood glucose levels, particularly for patients who have diabetes. Patients with a history of depression or other psychiatric disorders are also subject to careful observation during therapy.

Q: Is Suprecur MP considered a high-risk medication?

A: Official safety documents list several serious risks associated with this class of drug (GnRH agonists). These risks include an increased risk of cardiovascular events, such as heart attack or stroke, and a loss of bone mineral density over long periods of use, which may increase the risk of fracture.

Q: Is it safe to drive or operate machinery while using Suprecur MP?

A: Official product information states that certain side effects, such as dizziness, sleep disturbances, tiredness, or drowsiness, may impair a patient's ability to react and concentrate. For this reason, regulatory labels contain a warning against driving vehicles or operating tools or machinery if these effects are experienced.

Q: Does Suprecur MP affect the results of blood tests?

A: Yes, the official patient information indicates that the use of this medicine may influence the results of certain blood tests. This can include changes in the measured levels of liver enzymes and various fats (lipids) in the blood.

Q: Are there any documented cases of Suprecur MP overdose?

A: Regulatory documents list the symptoms associated with an overdose of buserelin. These symptoms can include feeling weak, nervous, dizzy, and sick, along with headache, hot flushes, stomach pain, leg swelling, and breast pain. Official product information advises that professional medical support is necessary if an overdose is suspected.

Q: Does Suprecur MP affect sleep patterns?

A: Official documentation lists sleep disturbances as an occasional or rare side effect. This is a potential adverse reaction that is reported in the safety profile.

Q: Is there a link between Suprecur MP and changes in vision?

A: Official adverse reaction data includes a link between buserelin and changes in vision. Impaired vision (e.g., blurred vision) and a feeling of pressure behind the eyes are listed as very rare or occasional side effects.

Storage and Disposal of Suprecur Injection

Official regulatory documents define specific conditions for storing Suprecur (buserelin) to maintain product integrity.

---

Storage Requirements

The unopened injection solution must be stored at a temperature below 25 °C. It is mandatory not to freeze the product. To ensure stability, the vial must be kept in the outer carton to protect from light. After the multidose vial is opened, the solution must be used within 15 days.

---

Safety and Disposal

Suprecur must be kept out of the sight and reach of children.

Any unused medicine, expired product, or waste material must be disposed of in accordance with local requirements. A partially used vial should be discarded after the treatment course is complete.